	Case 2:17-cv-12872-MCA-CLW Document 3	1 Filed 02/21/17	Page 1 of 29 PageID: 1	
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15	Patrick J. Reilly (Bar # 6103) preilly@hollandhart.com HOLLAND & HART 9555 Hillwood Drive, 2nd Floor Las Vegas, Nevada 89134 Telephone: (702) 222-2542 Jonathan M. Weiss (pro hac vice forthcoming) jonathan.weiss@kirkland.com Diana Torres (pro hac vice forthcoming) diana.torres@kirkland.com KIRKLAND & ELLIS LLP 333 South Hope Street Los Angeles, California 90071 Telephone: (213) 680-8400 Reed S. Oslan (pro hac vice forthcoming) reed.oslan@kirkland.com Justin A. Barker (pro hac vice forthcoming) justin.barker@kirkland.com KIRKLAND & ELLIS LLP 300 North LaSalle Chicago, Illinois 60654 Telephone: (312) 862-2000 <i>Attorneys for Plaintiff</i> <i>Absorption Pharmaceuticals, LLC</i>			
16 17	UNITED STATES DISTRICT COURT DISTRICT OF NEVADA			
17 18 19	ABSORPTION PHARMACEUTICALS, LLC, a Delaware limited liability company,	Case No.		
20	Plaintiff,	MISAPPRO	T FOR TRADE SECRET PRIATION; TORTIOUS	
21	- VS	INTERFERI INJUNCTIV	ENCE; FRAUD; AND E RELIEF	
22	RECKITT BENCKISER, LLC, a Delaware limited liability company; and DOES 1–50,	Jury Trial D	amandad	
23	Defendants.	Jury Ina D	emanueu	
24				
25				
26				
27	Plaintiff Absorption Pharmaceuticals, LLC ("Absorption") brings this action for damages and			
27 28			c c	
27 28	injunctive relief arising from trade secret misappro		c c	
			c c	

Reckitt Benckiser, LLC ("RB"). The allegations herein are made based on personal knowledge as to Plaintiff and its own actions and interactions, and upon information and belief as to all other matters.

1

2

3

NATURE OF THE ACTION

1. 4 This is a case about theft and fraud. For nearly two years, RB—part of a large and global 5 conglomerate that owns such household brands as Lysol, Mucinex, Air Wick, Woolite, Durex, and K-6 Y—extracted a wealth of confidential sales, marketing, product, and manufacturing information about 7 Absorption's highly successful premature ejaculation ("PE") product—Promescent®—under the guise 8 that RB was considering acquiring Absorption. Throughout discussions around the potential sale, both 9 RB and Absorption understood that the crucial customer, sales, marketing, product, and manufacturing 10 information that Absorption provided to RB in a good faith effort to move towards a transaction with 11 RB was confidential, trade secret information. Nonetheless, in September of 2016, RB launched its own 12 competing PE product called Duration, and misappropriated the confidential sales, marketing, product, 13 and manufacturing information that Absorption had shared. After developing its own product using 14 Absorption's confidential and proprietary information, RB broke off negotiations to purchase 15 Absorption.

In addition to stealing Absorption's trade secrets, RB set out to ensure that Absorption
 could not compete. RB deliberately interfered with Absorption's efforts to market Promescent® by,
 among other things, wrongfully taking Absorption's shelf space in Target stores and causing Amazon to
 hide Promescent®'s listing while redirecting customers to Duration.

3. Before the events giving rise to this litigation, plaintiff Absorption's Promescent® was
poised to do for premature ejaculation ("PE") what Viagra did for erectile dysfunction. The PE market
was poised to achieve unprecedented success, and Absorption was ideally positioned to capture that
opportunity through the combination of a uniquely effective PE treatment and hard-earned, inside
knowledge of the market. However, RB stole this opportunity from Promescent® by theft, artifice, and
deceit.

4. Absorption brings this complaint to hold RB accountable for its willful misappropriation
of Absorption's trade secrets, fraudulent sham-acquisition process, and ongoing efforts to destroy
Absorption's business and to remedy the severe injury that RB has inflicted and continues to inflict on

Absorption. Among other relief, Absorption seeks compensatory damages in excess of \$150 million, exemplary damages, attorneys' fees, and an injunction that enjoins RB from, among other things, selling, distributing, marketing or otherwise commercially using its Duration product.

JURISDICTION AND VENUE

5. This Court has subject matter jurisdiction under 28 U.S.C. § 1331 because this action arises, in part, under the federal Defend Trade Secrets Act, 18 U.S.C. § 1832. This Court has jurisdiction over Absorption's state law claims under 28 U.S.C. § 1332 because the parties are of diverse citizenship and the amount in controversy exceeds \$75,000, exclusive of interest and costs.

6. This Court has personal jurisdiction over Defendants because Defendants conduct or
have conducted substantial business and have promoted their Duration products in the state of Nevada
and this District, have purposefully availed themselves of the privilege of conducting business in
Nevada, have contracted directly with a company located in Nevada (Absorption), have misappropriated
trade secrets that they obtained from Nevada, and have harmed and continue to harm Absorption in this
District by misappropriating and using Absorption's trade secrets and interfering with Absorption's
contracts and business opportunities.

7. Venue is proper under 28 U.S.C. § 1391 because a substantial part of the events or
omissions giving rise to this action occurred in this District, in Clark County, Nevada. Venue lies in the
Southern Division of this Court.

THE PARTIES

8. Plaintiff Absorption is a limited liability company organized and existing under the laws
of the state of Delaware, with its principal place of business in Las Vegas, Nevada.

9. Defendant RB is a limited liability company organized and existing under the laws of the
state of Delaware, with its principal place of business in Parsippany, New Jersey. There is complete
diversity of citizenship because none of RB's members is a citizen of the same state as any of
Absorption's members. RB manufactures and distributes household products under numerous popular
brands, including Lysol, Air Wick, Mucinex, Dr. Scholl's, Woolite, Clearasil, Frank's RedHot, French's
Mustard, Airborne, Finish, Vanish, Veet, Durex, and K-Y.

28

19

1

2

3

4

5

6

7

8

1 10. The true names and capacities, whether individual, corporate, associate, or otherwise, of
 2 DOES 1 through 50, inclusive, are unknown to Absorption, who therefore sues said Defendants by such
 3 fictitious names and will ask leave to amend the Complaint to show their true names and capacities
 4 when they have been ascertained. Absorption is informed and believes and thereon alleges that each of
 5 the Defendants designated herein as DOE is responsible in some manner for the events and happenings
 6 referred to in this Complaint.

7 8

9

11. At all relevant times, all Defendants were agents of and acting on behalf of each other.

FACTUAL ALLEGATIONS

Absorption's History and Rapid Success

10 12. PE is the most prevalent sexual dysfunction in males—more common than erectile
11 dysfunction. Nevertheless, only a small fraction of sufferers consult a physician and even fewer receive
12 satisfactory treatment.

13

14

15

16

17

13. Prior to Promescent®, there was no clinically proven, over-the-counter treatment for PE.
14. Absorption was founded by urologist Dr. Ronald Gilbert, who developed Promescent® to give men an effective cure for PE and to close the "arousal gap" between men and women. Clinical studies demonstrate that Promescent®, by delaying ejaculation in men, helps close this gap.
Promescent® is an FDA-monograph-compliant lidocaine spray that is available over the counter.

18 15. Since Promescent[®]'s 2011 launch, it has grown into a multi-million dollar product. 19 Indeed, by 2012, Absorption had already attracted the attention of Auxilium, a much larger 20 pharmaceutical company that saw Promescent's potential and approached Absorption to discuss a 21 possible acquisition. After careful consideration, Absorption decided to remain independent while it 22 built its business. But a determined Auxilium kept pursuing Absorption over the ensuing months. Its 23 efforts culminated in an offer on January 27, 2013 with upfront cash, sales milestone earn-outs, and 24 future royalties worth over \$150 million. Elated, Jeff Abraham, Absorption's Chief Executive Officer, 25 shared the news with his best friend, next door neighbor, and co-founder Dr. Ron Gilbert.

16. The next day, Dr. Gilbert was murdered in a case of mistaken identity. Abraham,
distraught at his friend's tragic death, put off responding to Auxilium's offer, which Auxilium held open
indefinitely. Abraham relocated to Summerlin, Nevada two months later to escape the daily reminders

of his friend which surrounded him in their Orange County neighborhood. There, he resolved to redouble his efforts to make Absorption a success and create a fitting legacy for Dr. Gilbert and his family.

4 17. Absorption's website has a page dedicated to Dr. Gilbert, recognizing his vital 5 contributions to the success of Promescent[®], which was for him a labor of professional love. Abraham 6 requested as a condition of RB's acquisition of Absorption that RB maintain the page honoring Dr. 7 Gilbert. When Abraham told RB the story of Dr. Gilbert and Abraham's desire to honor his memory, 8 RB commended Abraham and stated that RB had a "moral obligation" to honor Dr. Gilbert. According 9 to RB, "It simply is the right thing to do!" From: Sydow, Volker [mailto:Volker.Sydow@rb.com] 10 Sent: Sunday, June 08, 2014 4:36 AM To: Jeff Abraham Subject: RE: dh / RE: Mayo - Premature Ejaculation web pages 11 Jeff, 12 No worries at all. I think this is something we certainly will do simply due to the moral obligation we have. It simply is the right thing to do! All the best. Volker 13 14 HEALTH . HYGIENE . HOME 15 ⊈ b 🗲 in 🚻 🗾 🍮 From: Jeff Abraham [mailto:jeff.abraham@promescent.com] 16 Sent: 06 June 2014 20:41 To: Sydow, Volker Subject: RE: dh / RE: Mayo - Premature Ejaculation web pages 17 Volker. 18 One thing I didn't bring up that I very important to me personally that I would ask RB to consider. Ron was the inventor and really the person who brought Promescent to life. There is a picture of him and a brief description of him on our site and it says "in memorium." Both 19 Auxilium and GSK have agreed that if we do the deal with them they will do something similar, very tasteful and just really listed in the part of how the product came about or under it management page. His wife and boys tell me they look at it often and it is a source of pride for them. Nothing that we need in writing and it certainly would not be a deal breaker but something to think about. 20

18. Promescent®'s initial success was due largely to its innovative proprietary formula and
unique marketing strategies. Promescent® is currently the only over-the-counter product available in
the United States that has been clinically proven to treat PE effectively. Additionally, Absorption's
marketing of Promescent® is singularly innovative: Contrary to the conventional wisdom in the
industry, Absorption positioned Promescent® as a premium branded and priced product. Absorption
also specifically designed its distribution and packaging strategies based on its proprietary understanding

28

21

1

2

of PE treatment consumers' demands. Absorption also similarly tailored its promotional and marketing efforts.

1

2

3 19. Promescent® garnered attention. Promescent® has been featured in numerous media
4 outlets, including Men's Health, CNBC, CNN, Men's Fitness, Esquire, Cosmopolitan, MSNBC, and Dr.
5 Oz. It has also been endorsed by a large number of medical professionals.

6 20. Promescent® is sold to consumers online, through individual provider practices, and in
7 selected brick-and-mortar stores.

8 21. Absorption's marketing strategy is groundbreaking in this sphere: Absorption markets
9 Promescent® as a premium product. Promescent® is available in two sizes: A travel trial size small
10 enough to fit in a pocket and a larger standard-size bottle. Absorption also offers various bundles of
11 these bottles, including a "home and away" bundle that combines a travel trial size with a standard-size
12 bottle.

22. 13 Given the prevalence of PE and potential recreational users, Absorption knew that the PE 14 treatment market was an untapped goldmine waiting for someone to come in and establish itself as the 15 market leader. Absorption thus felt the need to expand its distribution quickly to major retailers and to 16 launch a massive marketing campaign—and to do so before anyone else beat it to the punch. 17 Absorption was also particularly interested in expanding to Southeast Asia and India, which it believed 18 had an even larger demand for Promescent® than the United States due to increased prevalence of PE in 19 these regions. For example, a 2010 survey found that PE is one of the most common complaints 20 amongst Indian men—with greater than 50% of respondents complaining of PE. See India Today, The 21 New Pleasure Pill for Men (Jan. 27, 2011) (citing 2010 ORG IMS study), available at 22 http://indiatoday.intoday.in/story/the-new-pleasure-pill-for-men/1/126689.html.

23 23. By 2014, Absorption was realizing exponential revenue growth—particularly strong
24 given Absorption's size. To capitalize on its rapid success and secure its place as the market leader for a
25 long time to come, the small company felt that having the resources of a corporate partner with a large
26 global presence could more quickly take Promescent® to the next level. Auxilium was still interested
27 and, indeed, kept its attractive opening offer on the table. Around this time, RB also approached
28 Absorption saying it was interested in an acquisition.

1 2

RB's Business and Failed Foray into PE

24. RB is part of a large corporate family with operations worldwide, including Southeast 3 Asia and India. In fact, RB touts India as poised to become one of RB's top three markets. RB's CEO, 4 Rakesh Kapoor, was born and educated in India. Among other positions, he was RB's General Manager 5 for the Indian Southern Region and the Regional Marketing Director of South Asia before eventually 6 becoming CEO.

7 25. RB's brands are highly recognizable. It is the maker of popular household products sold 8 under brand names including Lysol, Air Wick, Mucinex, Dr. Scholl's, Woolite, Clearasil, Durex, and 9 K-Y.

10 26. In recent years, RB has come under significant public scrutiny for several corporate 11 scandals. In December 2016, RB was fined millions of dollars by an Australian court for deceiving 12 consumers. In early January 2017, a former executive at RB's South Korean sister company was 13 sentenced to seven years in prison because of the sale of a toxic disinfectant linked to hundreds of lung 14 injuries and over 50 deaths. And, late last year, 41 states and the District of Columbia brought a lawsuit 15 against RB for allegedly fabricating safety claims in order to delay the arrival of generic competitors to 16 Suboxone, a drug manufactured by RB to combat opioid addiction, and thereby maintain its monopoly 17 profits at the expense of recovering heroin and other opioid addicts. The Colorado Attorney General, 18 among the dozens of state attorneys general suing RB, accused RB of "shamelessly preying on patients 19 in need of help" and vowed to "hold them accountable for their unconscionable tactics." Suboxone 20 accounted for as much as 20% of RB's global profits in recent years.

21 27. Additionally, RB has a history of misappropriating small companies' intellectual 22 property. For example, in April 2016, in a case with remarkably similar overtones to the one here, RB 23 was sued by Poo~Pourri Products, which makes industry-leading toilet deodorizers. According to 24 Poo~Pourri, RB met with Poo~Pourri's prospective distributor, copied Poo~Pourri's product, packaging 25 and promotional materials (which RB passed off as its own), and thereafter caused the distributor to 26 back out of its deal with Poo-Pourri, and instead to distribute RB's competing product. RB also 27 allegedly infringed on Poo~Pourri's trademarks, trade dress, and copyright.

1

2

3

28. Given these incidents and what one commentator recently characterized as the aggressive "gung-ho" corporate culture permeating RB, there have been calls to slash the salary of RB's CEO, Kapoor, who, in 2015, was reportedly the third-highest-paid CEO at a U.K. public company.

4 29. In March 2014, RB acquired the K-Y brand from Johnson & Johnson and thereafter
5 began looking for opportunities to expand the K-Y product line. As part of this effort, RB hired Stephen
6 De Pretre as an acquisition consultant. Notably, PE was not on the list of potential product categories
7 that RB provided. De Pretre nevertheless suggested that RB look into acquiring Absorption.

30. Years prior, RB had marketed a PE treatment under its Durex label. The Durex PE
treatment was a cheap product that failed to penetrate the market and fizzled fast. Thus, when RB first
began looking for expansion opportunities, it was not interested in a PE product. RB did not believe that
a lidocaine-based PE spray could be effective or that one could earn sufficient profits to justify entering
the PE market.

31. Nevertheless, RB was apparently curious about Absorption after De Pretre presented the
company to RB as a promising target. Thus, in May 2014, Corrie Mueller, then Marketing Category
Manager for Durex, ordered 8 bottles of Promescent® to RB's affiliate in Beijing, China. After
receiving these bottles, RB's executives became convinced that Absorption had unlocked a secret to
success that RB's prior Durex offering had lacked.

18 32. In May 2014, Mueller set up a telephone conference between Reckitt Benckiser 19 Household Products (China) Co. Ltd.'s ("RB China") and Absorption. Mueller provided a list of talking 20 points for the meeting, which included the company's financial overview, supply and distribution chain 21 details, and marketing overview. She also offered to have personnel from RB China's legal department 22 on the call. RB China and Absorption also entered into a "Mutual Confidentiality Agreement." When 23 RB China signed this agreement and at all other relevant times, it intended to obtain Absorption's 24 proprietary information to use wrongfully for its own benefit (and to Absorption's detriment). Tellingly, 25 the only change RB China made to Absorption's proposed Mutual Confidentiality Agreement was the 26 last minute addition of an English choice of law clause and a permissive arbitration clause providing for 27 the possibility of arbitration in London. The United Kingdom does not provide statutory protection for 28 trade secrets. Consistent with RB's history of misappropriating small companies' intellectual property,

RB China made this change in anticipation of stealing Absorption's trade secrets and proprietary information. RB China thus made this change to the Mutual Confidentiality Agreement in bad faith.

3 33. The initial telephone conference included Abraham and Aditya Sehgal (then General
4 Manager of RB China). The call apparently went well, and talks between the two companies progressed
5 rapidly.

6 34. On June 4, 2014, Absorption's Abraham met with Volker Sydow, RB Global Category
7 Director, Sexual Wellness Products, in New York City. At all relevant times, Sydow was acting on
8 behalf and for the benefit of RB.

9 35. At the start of this meeting, Volker announced to Abraham that he needed to understand 10 two things before proceeding: (1) that RB did not believe that a lidocaine-based PE spray can work, and 11 (2) that RB did not believe that the market for a PE spray is large enough to justify entry. He thus 12 defined the two areas on which Absorption should focus its information disclosures in the due diligence process to come. During this meeting, Abraham presented¹ to Sydow information about the potential 13 14 size of the PE market and broader market for consumers looking to bridge the "arousal gap." During 15 this presentation, Abraham explained to Sydow the "arousal gap," and how to market Promescent[®] to 16 consumers who would otherwise use ineffective home remedies. This presentation also included 17 information about Promescent®'s advantages over other competitors. Sydow was so impressed that he 18 asked Abraham to meet with Mueller in Las Vegas the very next day (which he did).

19 36. Throughout these initial contacts, Abraham stressed to RB and its personnel that the PE
20 market was a new frontier that had not yet been broken by any mainstream market leader, and that this
21 acquisition was an opportunity to do just that—to establish Promescent® as the dominant market leader.

37. Sydow quickly recognized Promescent®'s potential. On June 8, 2014, Sydow thanked
Abraham for giving him Promescent® samples and raved about it: "[p]roduct is good, no worries! We
just need to understand the consumer story around it—the more you have done and you can share, the
better." (Emphasis added.)

26

27

28

1

¹ The presentation began with a slide that contained a confidentiality agreement and stated that by viewing the document the recipient agrees to keep the information in the presentation confidential.

38. In the same month, Sydow told Absorption that it planned to offer Absorption \$20
 million cash and a six percent (6%) royalty on product sales.

3

4

5

6

RB Probes Absorption for Proprietary Data Under the Guise of "Due Diligence"

39. RB obviously liked what it learned during its first forays with Promescent®, and thereafter continued to court Absorption aggressively, diving head first into "due diligence" for what it called "Project Speedy."

40. Less than ten days after telling Abraham that Promescent® is a good product, Sydow
informed Abraham that RB's CEO (Kapoor) had given him the "go ahead" to look "into detail" at
Absorption's "fabulous" Promescent® product.

41. Thus, on June 25, 2014, the parties held a "kick-off" telephone conference and RB sent a
spreadsheet with over 60 detailed "due diligence questions" which it wanted Absorption to answer about
15 topics, including Absorption's business and market, finance and accounting, intellectual property,
regulatory, information technology, supply, market research and consumer, technology, and marketing
and communication.

15 42. Faced with the prospect of disclosing Absorption's highly-valuable trade secrets, 16 Abraham sought reassurance that RB's interest was serious. He conveyed to RB that Absorption's 17 investors were uneasy because Absorption had another acquisition offer that would expire if not acted 18 upon and RB still had not provided the term sheet that Absorption had requested. RB's Corporate 19 Development Director, Kavan Stewart, called Abraham and assured him verbally of RB's intention to 20 move forward with an acquisition. At all relevant times, Stewart was acting on behalf and for the 21 benefit of RB. Sydow also assured Abraham that "[g]etting a royalty from a much larger pie is the big 22 price to win with RB" and thus assessing the potential size of the pie "is the core exercise we need to 23 run." (Emphasis added.)

43. Having been mollified by Sydow and Stewart, Absorption sent RB the first two "due
diligence" responses (about Absorption's patents and trademarks), as a gesture of "good faith."

44. The next day, Sydow informed Abraham that some "internal (very senior..) colleagues"
to whom Sydow had given Promescent® samples had just informed him that "THEY THINK IT IS

	Case 2:17-cv-12872-MCA-CLW Document 1 Filed 02/21/17 Page 11 of 29 PageID: 11			
1	FANTASTIC. IT REALLY WORKS." Sydow also asked Abraham to send more Promescent®			
2	samples to RB's offices.			
3	From: Sydow, Volker [mailto:Volker.Sydow@rb.com] Sent: Thursday, June 26, 2014 9:02 AM			
4	To: jeff.abraham@promescent.com Subject:			
5	Jeff, got some feedback from internal (very senior) colleagues of mine to whom I supplied P. samples to. THEY THINK IT			
6	IS FANTASTIC. IT REALLY WORKS Just wanted to let you know not that I did not know before And of course I'd like to order more samples. However, you just told me that you do not ship any more to outside of the			
7				
8	Regards Volker			
9				
10	45. On June 30, 2014, Abraham complained to Sydow that he still had not heard anything			
11	from Stewart about a term sheet and warned RB that he anticipated beginning due diligence with another			
12	company soon. In his email, Abraham also emphasized the need to move quickly to establish			
13	Promescent® as "THE" market leader.			
14	46. On July 9, 2014, Brian Robertson, RB's Senior Vice President of Corporate			
15	Development, and Stewart sent to Absorption a letter acknowledging that Absorption had received			
16	interest from other parties, but insisting on the superiority of RB's brands and global presence (including			
17	in China and India). The RB executives concluded their letter by asking Absorption to "bear with us			
18	and continue to help us in our due diligence effort" so they could put together a proposal including			
19	their "thoughts on economic terms." (Emphasis added). Finally, they expressed their expectation to be			
20	"in a position to formalize a proposal to you within 30 days."			
21	47. Thus, RB had assured Absorption that it believed in the Promescent® product, intended			
22	to make an offer, and that the key issue for RB was determining the size of the potential market for			
23	Promescent®. Absorption was well aware of the size of the market for its product, and therefore knew			
24	this would not be an issue. On the basis of this knowledge and RB's assurances, Absorption proceeded			
25	to unveil its most valuable trade secrets.			
26	48. During the ensuing weeks, Absorption responded to RB's "due diligence" requests by			

48. During the ensuing weeks, Absorption responded to RB's "due diligence" requests by providing numerous documents detailing Absorption's proprietary information regarding its customers,

marketing, business strategy, sales, profit margins, distribution, patents, and formulation (including
detailed step-by-step manufacturing instructions regarding Promescent®'s production). RB placed
particular emphasis on Absorption's profit margins, customer retention rates, customer purchasing
patterns, and the impact of media coverage on sales. Absorption provided to RB all of the information
that it requested.

49. Additionally, at a later date and after De Pretre had started working for Absorption, De
Pretre met with Sydow. During that meeting, Sydow showed De Pretre tests that RB was conducting of
Promescent®. These tests involved spraying Promescent® on skin from human cadavers to monitor the
degree of absorption. During this meeting, De Pretre shared Absorption's secret information regarding
what makes Promescent® effective.

11 50. Throughout the "due diligence" process, Abraham and Sydow also had numerous 12 conversations during which Abraham would explain the key aspects of Absorption's business and 13 marketing strategies. For example, Abraham explained the reasoning behind and importance of selling 14 both online and in brick-and-mortar stores. He also disclosed his ideas for how to market Promescent® 15 to position it for both therapeutic and recreational use. During at least one of these conversations, 16 Sydow stated that RB's market power was so strong that it could induce retailers—including Target—to 17 take shelf space away from other companies' products to immediately make room for RB's products. 18 Sydow also stated to Abraham that RB has significant influence over Amazon.com. In particular, 19 Sydow emphasized that RB made Amazon nearly a hundred million dollars in commissions on its 20 products annually and said that "Amazon does not tell us what to do, we tell Amazon what to do." 21 Alexander Lacik, President of RB's North American operations, also made similar comments.

51. Throughout the Project Speedy "due diligence" process, RB continually delayed
committing to a formal offer with excuses and promises that a formal offer would be forthcoming. For
example, sometime between July 9 and August 18, 2014, after Abraham complained that Absorption
still had not received a formal offer, Sydow informed him that an offer was sitting on Kapoor's desk and
waiting for a signature. Such statements were false and made to keep Absorption from moving forward
with an acquisition by another company.

28

52. In the midst of this process, RB asked Absorption to send 15 kilograms of bulk product
 for "condom testing." This is enough Promescent® to fill thousands of standard-sized bottles. At the
 time, Absorption did not have experience with this type of testing and thus did not know the quantity of
 product required. However, it later learned that this quantity is far in excess of anything that RB could
 reasonably need for condom testing.

53. In mid-July 2015, Abraham had a phone call with Stewart in which Stewart assured
Abraham that an offer would be forthcoming. While RB did not give any concrete terms, Stewart
claimed that the offer would be something less than the \$20 million cash that had been previously
discussed, but that the royalty would go from six percent (6%) to ten percent (10%).

54. On August 18, 2014, Abraham met with Lacik in Parsippany, New Jersey. During this
meeting, Lacik asked numerous questions about Absorption's customers and customer retention.
Abraham showed Lacik Promescent.com's "transactional portal" which contained Absorption's order
history and trends, including repeat customer percentages. Lacik exclaimed that he "ha[d] to have this
product and put it in [RB's] KY line. It is a perfect fit!" During the meeting, Lacik started composing
an email to Kapoor (which he showed to Abraham) conveying Lacik's support of acquiring Absorption.

16 55. Lacik understood the potential size of the PE market and that the Absorption acquisition
17 would be an opportunity to establish a product as the leader in this untapped market. RB, however, had
18 no intention of lawfully acquiring Absorption, but sought only to acquire unlawfully Absorption's trade
19 secrets.

20

<u>RB Abruptly Ends Negotiations</u>

56. After this meeting, rather than convey the long-promised acquisition offer, RB informed
Absorption that it wanted to conduct an outside market study to validate the size of the potential market
before committing to a formal offer. Abraham asked Sydow to provide a copy of any study generated.
Sydow responded that he was willing and anticipated being able to do so. Around the same time, RB
also raised questions regarding regulatory issues concerning Promescent®.

26 57. RB was not actually concerned about either the market size or any regulatory issues.
27 Instead, it simply wanted to stall talks with Absorption while RB developed its own competing product.
28 Nevertheless, RB verbally assured Absorption that a potential deal was "still live."

Case 2:17-cv-12872-MCA-CLW Document 1 Filed 02/21/17 Page 14 of 29 PageID: 14

58. During the ensuing months, RB continued assuring Absorption of its continued interest every time Absorption indicated that it was growing impatient and considering other options. For example, on October 23, 2014, Abraham told Sydow that he was being pressured to send a letter to RB informing them that negotiations appeared to be at an end. On roughly the same date, Sydow sent Abraham a text message saying "don't sign anything [with any other company.]" At the time, Absorption had been approached by another company about a potential acquisition, but declined to pursue the opportunity in reliance on RB's assurances of an intent to enter into a deal and on Sydow's urgings to not sign with another company.

- 9 59. When RB's outside market study concluded, Sydow informed Abraham that it showed
 10 that the market was not as large as Absorption had thought. Instead, RB's study supposedly forecasted a
 11 market of \$30-\$40 million from advertising spending of \$10 million. Nevertheless, Sydow informed
 12 Abraham that a deal with Absorption was still very possible. Sydow thereafter told Abraham that RB
 13 intended to present all of the information to Kapoor in late January 2015.
- 60. At the end of January, Sydow informed Abraham that he had presented the Absorption
 acquisition to Kapoor and that they needed to have a follow-up meeting, which he then claimed was
 delayed. Abraham emailed Sydow and informed him that Absorption was in talks with other companies
 and that he was facing tremendous pressure to move forward with those companies rather than RB.

	Case 2:17-cv-12872-MCA-CLW Document 1 Filed 02/21/17 Page 15 of 29 PageID: 15					
1	From: Jeff Abraham					
2	Sent: Thursday, January 22, 2015 12:31 PM To: Svdow, Volker					
2	To: Sydow, Volker Subject: Sorry for the outburst					
3	Follow Up Flag: Follow up					
4	Flag Status: Flagged					
5						
6	Volker,					
7	I am under tremendous pressure right now and our Chief medical officer is the guy who is connected to Perrigo and he is all over me asking why I am putting them off. We are really taking off and I don't want to hire people if we are getting acquired					
8	soon and I am now literally working 24/7. I am working on a new manufacturing run and have some excellent promotional opportunities and it is just overwhelming. Our shareholders have felt for a long time that I am completely intent on RB only and if this falls apart again I am going to get tarred and feathered. I will work the others in parallel and just hope this happens.					
9	I just know that getting in the deep due diligence takes so much of my time that it is draining. I know you are doing all you can, please let me know however if at some point it appears RB is not really sold on Promescent.					
10	Jeff Abraham					
11	CEO Absorption Pharmaceuticals					
12	702-228-046					
13						
14	PROMESCENT® MAKE LOVE LONGER					
15						
16	61. Sydow again mollified Abraham, assuring him that RB was not deliberately delaying					
17						
18	progress, that a deal was imminent, and to hold off on pursuing other opportunities for just a little while					
19	longer.					
20	62. Around January 28, 2015, Abraham had a phone conversation with Sydow in which he					
21	accused RB of creating its own "knock off" PE spray. Sydow assured Abraham that RB was not					
22	knocking off Promescent. However, in reality, that is exactly what RB was planning to do.					
23	63. In the ensuing months, Abraham repeatedly asked Sydow to share details of RB's marke					
24	survey analysis, puzzled by a market forecast that was orders of magnitude smaller than Absorption's					
25	customer data and sales information projected and supported. Contrary to his earlier representations,					
26	Sydow claimed that he could not share this "confidential" information, and thus RB never shared any					
27	information about its supposed market study with Absorption.					

64. 1 In April 2015, Absorption learned from a reliable source that RB was planning to launch 2 a lidocaine-based PE spray. It was unclear from this source whether that spray would be Promescent® 3 or an RB knock-off. Abraham called Sydow and confronted him—demanding to know whether RB was 4 knocking off Promescent[®] or introducing its own spray for PE. Sydow assured Abraham that RB was 5 not knocking off Promescent[®] and was not introducing a spray for PE. Based on Sydow's 6 representations, Absorption did not investigate the issue further and took no steps to protect itself from 7 RB's launch of a competing product. However, unbeknownst to Absorption, Sydow was lying. At the 8 time, RB was actively planning to launch its own spray for PE.

9

10

11

65. For months thereafter, contact between Absorption and RB was sparse.

<u>While Preparing To Launch Its Own Product, RB Attempts To Obtain Updated Confidential</u> <u>Marketing and Technical Product Information From Absorption Under The Guise of Renewed</u> <u>Interest In A Deal</u>

12 66. Then, in late 2015, the parties reengaged. By December 2015, it appeared that RB had a
13 renewed interest in Absorption, and, through a communication from Sydow to De Pretre (who was then
14 working for Absorption), sought to obtain updated information about Absorption's sales, customers, and
15 new technological developments.

16 67. In January 2016, RB, through Sydow, again claimed to be interested in a deal with
17 Absorption. Sydow also stated that he wanted to "make sure we will set this up in a way that neither
18 side will be impacted negatively if we decide after these discussions that it will not be the right decision
19 for us to collaborate." The parties thus began negotiating a new NDA.

20 68. In February 2016, RB rejected the NDA that Absorption proposed, and instead submitted
21 a "Two Way Confidentiality Agreement" that was anything but mutual, and effectively left Absorption
22 without the ability to enforce it. Absorption rejected RB's proposal and ceased further communications
23 regarding a potential acquisition.

69. Nevertheless, between February and May 2016, RB's Research & Development
Department ordered nearly 70 bottles of Promescent® using a personal credit card for delivery to the
personal home address of the R&D department's director. RB refrained from using its business name,
address, and credit card because it wanted to avoid detection by Absorption.

70. On May 3, 2016, RB submitted an intent-to-use trademark application for K-Y for "[m]edicated sprays, liquids, gels and creams for desensitizing the penis and preventing premature 3 ejaculation." See U.S. Trademark Application Serial No. 87023826. In August 2016, RB submitted a 4 second intent-to-use application for "Last Longer Stay in the Moment" for use with the same category of 5 goods.

71. 6 Unbeknownst to Absorption, RB began producing the first batches of its competing 7 product—Duration—in June 2016.

8 72. On July 15, 2016, Sydow directed his assistant to resend to Abraham for signature the 9 new NDA which Abraham had previously rejected as unacceptably one-sided. The timing of this email 10 made no sense. The new NDA was purportedly in connection with renewed acquisition talks when in 11 reality RB had already registered an intent-to-use trademark for Duration and had begun manufacturing 12 the product. When Abraham questioned why she was suddenly re-sending out of the blue an agreement 13 that he had rejected months earlier, she claimed that she was "clearing up [her] emails and came across 14 that one [meaning the 'Two Way Confidentiality Agreement']."

15 73. A few weeks later, on September 1, 2016, RB launched Duration spray for men with the 16 largest marketing campaign in K-Y's history. RB invested \$40 to \$50 million in marketing alone, 17 reflecting a projected initial market of half a billion dollars. This was the same estimated initial market 18 size that Absorption's CEO had communicated to RB during RB's "due diligence" based on 19 extrapolations from Absorption's customer data and repeat user information. And yet, RB falsely 20 claimed to Absorption that its research found the PE market inadequate to justify an acquisition, with at 21 best a \$30 to \$40 million market.

22 Just as Absorption had positioned Promescent®, RB aimed its campaign to appeal to both 74. 23 therapeutic and recreational users. RB also put into use Absorption's confidential marketing strategies, 24 which RB had obtained during the "due diligence" process. And, like Absorption, RB made Duration 25 available in a small trial size and a larger standard-size bottle and offered it for sale both online and in 26 brick-and-mortar stores, using nearly identical price points to Promescent[®]. To add insult to injury, RB 27 launched Duration in a blue and white color scheme, strikingly similar to that of Promescent[®]. Indeed,

28

1

the packaging of Duration depicts a blue and white bottle that looks more like a bottle of Promescent® than a bottle of Duration.

75. In sum, RB strung Absorption along while it plundered Absorption's data and developed its own competing product. It also caused Absorption to forego other acquisition opportunities. Then, RB launched its own directly competitive PE treatment, which it has tried to establish as a market leader—thereby usurping the opportunity that Absorption had discovered and brought to RB's attention. And it did so by mimicking Promescent®'s packaging, marketing, and sales strategy—all in a transparent attempt to steal Absorption's hard-earned business.

<u>RB Knocks Promescent® Off Target's Shelves and Otherwise Interferes with Absorption's</u> <u>Business</u>

76. To ensure the success of Duration, RB had to make sure it faced no competition from Promescent[®]. To do this, it used its substantial market power to command retailers to place RB's new product in strategically beneficial positions and to cut out its competition—in this case, Promescent[®].

77. Around March 2016—before RB launched Duration—Absorption entered its biggestever distribution agreement: an agreement with retailer Target to begin stocking Promescent® on shelves in 1,600 stores starting in October 2016. Target agreed to carry 4 SKUs—2 small bottles and 2 large bottles. The agreement also required Absorption to create Target-specific packaging and to commit to a large advertising campaign. Reflecting Target's enthusiasm for carrying Promescent®, Absorption secured Target's agreement in one day.

78. Starting in May 2016, Absorption invested at least \$400,000 on Target-specific packaging and committed to a \$2 million advertising campaign.

79. Thereafter, Absorption also paid a substantial fee to register product codes for the products to be stocked in Target. These codes are made available to other producers with registered products, including RB.

80. In July 2016, Target suddenly informed Absorption that there were new product launches in the same category as Promescent® and it did not know if the space that it had committed to Absorption would be available in October. In the following weeks, Absorption confronted Target and demanded that Target honor its agreement to stock Promescent®. These discussions culminated in an

1

email from Target in August 2016 stating that it would not launch Promescent® in its stores in October. Upset about Target's sudden about-face, Abraham met with Target's executive buying team on August 10, 2016. During this meeting, Abraham confronted Target's executive about whether RB caused Target to divert Promescent®'s shelf space to Duration, specifically naming Sydow and Lacik as the RB individuals involved in this interference. Target did not deny Abraham's account and instead agreed to carry one trial size SKU of Promescent[®] in its retail stores but Absorption lost hundreds of thousands of dollars that it spent on Target-specific packaging for the three dropped SKUs and even more in lost business opportunities.

81. Target currently stocks its retail stores with 4 SKUs of Duration—the same configuration that it had originally promised to Promescent®. RB caused Promescent®'s sole SKU to be hidden within Duration displays.



82. RB also used its influence with Amazon.com to interfere with Promescent®'s distribution through that website. Although Promescent® had always been among the general merchandise at Amazon, shortly before Duration launched, Promescent® was suddenly relegated to the "hidden" "adult section" of Amazon.com. Products in the "adult section" do not appear as results of a standard search. Instead, the user must specifically click a button telling Amazon.com to display "adult"

Case 2:17-cv-12872-MCA-CLW Document 1 Filed 02/21/17 Page 20 of 29 PageID: 20

products responsive to the user's search. Though Duration is the same type of product as Absorption, it
was placed in a standard (non-"adult") category and thus received the full visibility that had previously
been afforded Promescent®. Lest there be any doubt that RB caused Promescent® to be specifically
singled out and hidden: Other similar (though far less successful and competitively threatening) PE
treatments were not flagged as "adult"—notwithstanding the sexually suggestive and explicit branding
of such products.

83. During this time, Absorption repeatedly complained to Amazon about the unequal
treatment that Promescent® received—beseeching Amazon to treat similarly situated products in the
same manner. Absorption repeatedly complained that if Promescent® was an "adult" product, then
Duration should be treated similarly. On several occasions, low level Amazon customer service
representatives moved Duration to the "adult section" when Absorption complained. However, each
time, Duration was moved back to a standard category in short order, while Promescent® inexplicably
remained in the "adult section."

84. After repeated complaints over an extended period of time to Amazon's "category
manager," including letters written by Absorption's counsel, the visibility of Promescent® as a general
merchandise (as opposed to "adult") product was finally restored; however, sales have not recovered.

17 85. To divert even more business from Absorption, RB used the registered trademark
18 Promescent® to direct Amazon users to Duration. For example, starting in the last week of September
19 2016, a user searching on Amazon.com for "Promescent" "Promescent Spray" was shown a list of
20 search results only to alternative products, with "Duration" appearing at the top of the search results.

86. RB also purchased the federally registered trademark "Promescent" as a keyword to
advertise RB's Duration product, thus causing advertisements for Duration to appear directly adjacent to
the purchase button on the Amazon.com listing for Promescent®. Not coincidentally, Absorption was
denied the ability to advertise Promescent® on Amazon.com using its own trademark—or any
trademark at all—even though Absorption had previously been allowed to do so. This, too, was RB's
doing.

27 87. RB further interfered with Absorption's distribution by causing banner ads to be placed
28 directly below the purchase button for Promescent® on Amazon.com. Given that RB also deliberately

Case 2:17-cv-12872-MCA-CLW Document 1 Filed 02/21/17 Page 21 of 29 PageID: 21


1

2

3

16

chose product packaging for Duration that depicted a bottle that was confusingly similar to Absorption's bottle, this ad was likely to cause substantial confusion and to divert customers from Promescent® to Duration.



17 88. Around the same time that RB interfered with Absorption's distribution on Amazon.com 18 and Absorption's contract with Target, a planned promotional television segment regarding Absorption 19 was bizarrely produced without any reference to Absorption or Promescent[®]. In September 2016, the 20 popular television show "The Doctors" planned to air a promotional segment featuring Promescent® 21 and the recently-concluded study showing Promescent®'s efficacy. The producers of "The Doctors" 22 agreed with Absorption's marketing firm to do so. Absorption provided "The Doctors" with 23 Promescent[®] product and arranged, at its expense, to fly the author of the study to Los Angeles for the 24 taping. Just prior to the scheduled flight, however, Absorption was informed that "The Doctors" no 25 longer intended to feature the study, despite the fact that the study had been of great interest to the 26 producers. Not only did the producers drop the reference to the study, when the segment aired on 27 September 29, 2016, there was no mention of Promescent® or Absorption at all. Instead, the segment 28 had been re-edited to eliminate all references to the product name but to suggest that the product was

Case 2:17-cv-12872-MCA-CLW Document 1 Filed 02/21/17 Page 22 of 29 PageID: 22

really Duration. The after-the-fact re-editing is apparent because at one point, one of the panel

2 physicians grabbed a bottle and states "It's called Pr—." See

3 <u>http://www.thedoctorstv.com/articles/3407-penis-spray-to-make-men-last-longe</u> (at 0:44).

89. Defendants' aforementioned actions have caused and will continue to cause Absorption to suffer irreparable harm. This injury will likely continue indefinitely unless Defendants' are restrained from such behavior.

COUNT I

(Against All Defendants)

Fraud

90. Absorption incorporates by reference and repeats the allegations contained in Paragraphs1 through 89 as though fully set forth herein.

12 91. As previously alleged herein, Defendants intentionally misrepresented or concealed 13 material facts from Absorption to induce Absorption to divulge its proprietary information and/or to 14 forego its opportunity to contract with Auxilium. For example, (1) Sydow represented that RB intended 15 to make an offer to acquire Absorption of \$20 million cash and a six percent (6%) royalty on product 16 sales; (2) Robertson and Stewart stated that RB intended to make a formal offer to acquire absorption 17 within 30 days; (3) Volker stated that RB was not deliberately delaying providing a formal offer; and (4) 18 Volker stated that RB was not creating a Promescent[®] knock off and was not introducing a spray for 19 PE.

20

1

4

5

6

7

8

9

10

11

92. At all relevant times, Defendants knew that each of these representations was false.

21 93. At all relevant times, Defendants intended to induce Absorption to divulge its proprietary
22 information and/or to forego its opportunity to contract with Auxilium or other companies in reliance on
23 Defendants' representations.

94. Absorption justifiably relied on Defendants' false representations. As a result of the
directions, actions, omissions, misrepresentations, and/or concealments effected by Defendants,
Absorption was induced to divulge its proprietary customer and business information, to forego the deal
with Auxilium, to forego opportunities with other companies, and to avoid taking steps to protect itself
against RB's launch of a competing product.

95. Absorption has thereby suffered lost profits, Defendants' unjust enrichment, and other
 harm in an amount to be proved at trial.

3 96. Defendants' conduct amounts to intentional concealment and/or misrepresentation of
4 facts known to them, made with the knowledge that such misdeeds would or could harm Absorption.
5 Such conduct was fraudulent, oppressive, or malicious, and was carried out in conscious disregard of
6 Absorption's rights, so as to justify an award of punitive damages.

7

8

9

10

11

COUNT II

(Against All Defendants)

Federal Trade Secret Misappropriation in violation of 18 U.S.C. §§ 1836, 1839

97. Absorption incorporates by reference and repeats the allegations contained in Paragraphs1 through 96 as though fully set forth herein.

98. Absorption's proprietary financial, product, manufacturing, marketing, business, and
customer information ("Trade Secrets") are statutory "trade secrets" protected by the Defend Trade
Secrets Act, 18 U.S.C. §§ 1836, 1839.

99. Absorption's Trade Secrets are sufficiently secret to derive economic value from not
being generally known to and not readily ascertainable through proper means by other persons who can
obtain economic value from their disclosure or use.

18 100. At all times, Absorption has taken reasonable measures to protect the secrecy and
19 confidentiality of Absorption's Trade Secrets, including by consistently requiring any parties to whom it
20 discloses any of its Trade Secrets to sign confidentiality agreements.

21 101. On or after May 11, 2016, the effective date of the Defend Trade Secrets Act, Defendants
22 actually misappropriated Absorption's Trade Secrets through improper acquisition, disclosure, and/or
23 use without Absorption's express or implied consent.

Defendants intentionally misappropriated Absorption Trade Secrets by, among other
things: (1) obtaining the information by falsely representing that they were interested in acquiring
Absorption; (2) inducing Absorption to share its Trade Secrets with the hidden intention of converting
them for Defendants' own use; and (3) improperly using the information to design, produce, market, and
sell a product directly competitive with Absorption's Promescent®.

1 103. The trade secret information misappropriated by Defendants is related to Duration, which
 2 is used in, and intended for use in, interstate or foreign commerce.

- 3 104. As competitors of Absorption, there is a genuine, imminent threat that Defendants will
 4 continue to use Absorption's Trade Secrets in the course of their business.
- 5 105. Absorption has suffered and will suffer damages, including, but not limited to, actual loss
 6 and unjust enrichment by Defendants, in an amount to be proven at trial, as a direct result of Defendants'
 7 misappropriation of Absorption's Trade Secrets.
- 8 106. Defendants' misappropriation of Absorption's Trade Secrets has been willful and
 9 malicious and entitles Absorption to exemplary damages and an award of attorneys' fees and costs
 10 pursuant to the Defend Trade Secrets Act, 18 U.S.C. § 1836(b)(3).
- 11 107. Absorption also is entitled to injunctive relief to prevent the misappropriation of
 12 Absorption's Trade Secrets by Defendants pursuant to the Defend Trade Secrets Act, 18 U.S.C.
 13 § 1836(b)(3). Defendants' misappropriation has caused and will cause Absorption to suffer substantial
 14 and irreparable harm, including the failure of its business, unless Defendants are enjoined from retaining
 15 and using Absorption's Trade Secrets, including by continued production and sale of Duration.

COUNT III

(Against All Defendants)

Nevada Trade Secret Misappropriation

19 108. Absorption incorporates by reference and repeats the allegations contained in Paragraphs
20 1 through 107 as though fully set forth herein.

21 109. Absorption's proprietary financial, product, manufacturing, marketing, business, and
22 customer information ("Trade Secrets") are statutory "trade secrets" protected by the Nevada Uniform
23 Trade Secrets Act, Nev. Rev. Statutes, Chapter 600A.

24 110. Absorption's Trade Secrets are sufficiently secret to derive economic value from not
25 being generally known to and not readily ascertainable through proper means by other persons who can
26 obtain economic value from their disclosure or use.

27

16

17

18

1 111. At all times, Absorption has taken reasonable measures to protect the secrecy and
 2 confidentiality of Absorption's Trade Secrets, including by consistently requiring any parties to whom it
 3 discloses any of its Trade Secrets to sign confidentiality agreements.

112. Defendants intentionally misappropriated Absorption Trade Secrets by, among other
things: (1) obtaining the information by falsely representing that they were interested in acquiring
Absorption; (2) inducing Absorption to share its Trade Secrets with the hidden intention of converting
them for Defendants' own use; and (3) improperly using the information to design, produce, market, and
sell a product directly competitive with Absorption's Promescent[®].

9 113. As competitors of Absorption, there is a genuine, imminent threat that Defendants will
10 continue to use Absorption's Trade Secrets in the course of their business.

11 114. Absorption has suffered and will suffer damages, including, but not limited to, actual loss
and unjust enrichment by Defendants, in an amount to be proven at trial, as a direct result of Defendants'
misappropriation of Absorption's Trade Secrets.

14 115. Defendants have engaged in willful, wanton, and reckless misappropriation of
15 Absorption's Trade Secrets and have disregarded Absorption's rights. Accordingly, Absorption is
16 entitled to exemplary damages under N.R.S. § 600A.050 and an award of attorneys' fees and costs
17 pursuant to N.R.S. § 600A.060.

18 116. Absorption also is entitled to injunctive relief to prevent the misappropriation of
19 Absorption's Trade Secrets by Defendants pursuant to N.R.S. § 600A.040. Defendants'
20 misappropriation has caused and will cause Absorption to suffer substantial and irreparable harm,
21 including the failure of its business, unless Defendants are enjoined from retaining and using
22 Absorption's Trade Secrets, including by continued production and sale of Duration.

COUNT IV

(Against All Defendants)

Intentional Interference with Contract

26 117. Absorption incorporates by reference and repeats the allegations contained in Paragraphs
27 1 through 116 as though fully set forth herein.

28

23

24

1 118. Absorption had valid and existing contracts: (1) with Target to distribute 4 SKUs of
 2 Promescent® in Target's stores; and (2) with Amazon to distribute Promescent® via its website.

3

119. Defendants knew of each of these two contracts.

4 120. Defendants intentionally acted to disrupt Absorption's contract by demanding that Target
5 refuse to honor the agreement to carry 4 Promescent® SKUs, and instead devote the shelf space
6 promised to Absorption to RB's Duration.

7 121. Absorption's contract with Target was actually disrupted. Target refused to carry all 4
8 Promescent® SKUs that it had originally agreed to stock in its retail stores. Instead, Target only stocked
9 1 Promescent® SKU—a travel trial size bottle.

10 122. Defendants intentionally acted to disrupt Absorption's contract by demanding that
 11 Amazon.com relegate Promescent® to the "adult" category and by demanding that Amazon.com act to
 12 divert customers searching for Promescent® to Defendant's competing Duration product.

13 123. Absorption's contract with Amazon.com was actually disrupted. For example, Amazon 14 improperly categorized Promescent® as an "adult" product and thereby relegated Promescent® to the 15 hidden "adult section"—even though the competitive Duration was not similarly categorized. 16 Additionally, an Amazon search using the federally trademarked term "Promescent" (or "Promescent 17 Spray") directed consumers to alternative products, with "Duration" appearing at the top of the search 18 results. Moreover, if a consumer were to tick the "Promescent" box to the left of the search results page, 19 the message "Your search 'promescent' did not match any products" appeared. These are only some of 20 the ways in which Absorption's contract with Amazon.com was disrupted.

124. Defendants' disruption of Absorption's contracts with Target and Amazon caused
Absorption harm. As a result of this disruption, Absorption lost at least \$400,000 that it spent in Targetspecific packaging, and also suffered actual damages, lost profits, Defendant's unjust enrichment, and
other harm in amounts to be proven at trial. Such conduct was fraudulent, oppressive, or malicious, and
was carried out in conscious disregard of Absorption's rights, so as to justify an award of punitive
damages.

- 27
- 28

1

2

3

COUNT V

(Against All Defendants)

Tortious Interference with Prospective Economic Advantage

4 125. Absorption incorporates by reference and repeats the allegations contained in Paragraphs
5 1 through 124 as though fully set forth herein.

6 126. There was a prospective contractual relationship between Absorption and Auxilium,
7 which had offered to acquire Absorption for as much as \$150 million.

8 127. To the extent that Absorption did not have actual contractual relationships with Target
9 and Amazon, Absorption had prospective contractual relationships with these entities.

10 128. Defendants were aware of Absorption's prospective contractual relationship with
11 Auxilium because Absorption repeatedly told them about this prospective relationship. Defendants were
12 also aware of Absorption's prospective contractual relationships with Target and Amazon.

129. Defendants intended to harm Absorption by preventing the relationship with Auxilium.
14 Defendants repeatedly told Absorption to wait and not sign any acquisition deals with the other
15 companies courting Absorption—including Auxilium. Defendants made these statements not because
16 RB intended to acquire Absorption, but solely because Defendants did not want Absorption to move
17 forward with another deal that would allow Absorption to expand Promescent®'s reach before RB could
18 create its own competing product.

19 130. Defendants intended to harm Absorption by preventing its relationships with Target and
20 Amazon. RB had boasted of its ability to interfere with other companies' distribution efforts at retailers
21 such as "Target" and "Amazon." RB was also aware that the PE market was ripe for a leader to emerge
22 and raise barriers to entry. RB interfered with Absorption's prospective contractual relationships
23 because RB wanted to ensure that Duration would beat out Promescent® (then the market leader) to
24 raise barriers to entry and capture the market.

131. No privilege or justification applies to Defendants' interference with Absorption's
prospective relationship with Auxilium, Target and Amazon.

27 132. Because of Defendants' wrongful actions, Absorption lost out on the lucrative
28 opportunity to be acquired by Auxilium. Absorption therefore suffered losses of at least \$150 million

and suffered other harm in amounts to be proven at trial. Because of Defendants' wrongful actions,
 Absorption also lost out on lucrative distribution opportunities with Target, lost significant sales volume
 on Amazon, and suffered other harms in amounts to be proven at trial.

4 133. Such conduct was fraudulent, oppressive, or malicious, and was carried out in conscious
5 disregard of Absorption's rights, so as to justify an award of punitive damages.

6 7

PRAYER FOR RELIEF

WHEREFORE, Plaintiff Absorption respectfully requests that the Court enter an Order:

8 1. Enjoining Defendants as well as their subsidiaries, partners, officers, agents, servants,
9 employees, attorneys, and all those acting in concert with them, from (1) using any of Absorption's
10 Trade Secrets; and (2) producing, marketing, or selling any product created using any of Absorption's
11 Trade Secrets, including K-Y Duration;

Awarding Absorption damages for actual losses, unjust enrichment, and/or reasonable
 royalties in accordance with 18 U.S.C. § 1836 and/or N.R.S. § 600A.050;

Awarding Absorption exemplary damages, costs, and reasonable attorneys' fees in
accordance with 18 U.S.C. § 1836(b)(3) and/or N.R.S. §§ 600A.050 & 600A.060;

4. Entering a judgment awarding Absorption compensatory and punitive damages in
connection with Absorption's claims for tortious interference and fraud, in an amount to be determined
at trial; and

19

20

22

23

24

25

26

27

28

5. Granting Absorption such other and further relief as this Court deems just and equitable.

21 Dated: February 21, 2017

Respectfully submitted,

/s/ Patrick J. Reilly

Patrick J. Reilly (Bar # 6103) preilly@hollandhart.com HOLLAND & HART 9555 Hillwood Drive, 2nd Floor Las Vegas, Nevada 89134

Jonathan M. Weiss (*pro hac vice forthcoming*) jonathan.weiss@kirkland.com Diana Torres (*pro hac vice forthcoming*)

	Case 2:17-cv-12872-MCA-CLW	Document 1 Filed 02/21/17 Page 29 of 29 PageID: 29
1		diana.torres@kirkland.com
2		KIRKLAND & ELLIS LLP 333 South Hope Street
3		Los Angeles, California 90071
4		Reed S. Oslan (<i>pro hac vice forthcoming</i>) reed.oslan@kirkland.com
5		Justin A. Barker (pro hac vice forthcoming)
6		justin.barker@kirkland.com KIRKLAND & ELLIS LLP 300 North LaSalle
7		Chicago, Illinois 60654
8		Attorneys for Plaintiff Absorption Pharmaceuticals, LLC
9		Thurmaceuricuis, ELC
10		
11		
12		
13		
14		
15		
16 17		
17 18		
18 19		
20		
20		
22		
23		
24		
25		
26		
27		
28		
		29